Navigation Links
Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
Date:11/4/2013

SAN DIEGO, Nov. 4, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the third quarter ended September 30, 2013, on Tuesday, November 12, 2013 prior to market open. The announcement will be followed by a live webcast and conference call at 8:30 a.m. Eastern time (5:30 a.m. Pacific time).

Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (888) 895-5479 (domestic) or (847) 619-6250 (international), participant code 36014873.

The following day, Orexigen management will present a company overview at the Credit Suisse Healthcare Conference in Scottsdale, Arizona. The presentation is scheduled for Wednesday, November 13th at 9:30 a.m. Mountain Time.  

The webcasts of the live and subsequently archived conference call and conference presentation can be accessed on the Investor Relations section of the Orexigen web site at www.orexigen.com and will be archived for 14 days following each event.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com

McDavid Stilwell
Vice President, Corporate Communications & Business Development
858-875-8600


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
2. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
3. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
4. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
5. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
6. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
7. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
8. Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast
9. Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference
10. Orexigen Therapeutics to Present at Upcoming Investor Conferences
11. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017  NuVasive, Inc. (NASDAQ: NUVA), ... spine surgery with minimally disruptive, procedurally-integrated solutions, today ... clearance of the CoRoent® Small Interbody™ System indicated ... in the cervical spine. This marks the first ... used at up to four contiguous levels. ...
(Date:3/29/2017)... , March 29, 2017 NetworkNewsWire ... ... the public safety in regulating marijuana, but economic arguments also ... creation, and reduced law enforcement costs. However, to legalize and ... provided by SinglePoint, Inc. (OTC: SING) ( SING Profile ), ...
(Date:3/29/2017)... - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical ... ended December 31, 2016 after market close on ... released later than the previous fiscal year,s results ... and balances of Apicore from the acquisition date ... date meets TSX Venture Exchange listed company requirements. ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 2017 , ... Tuesday, March 28, 2017, is the annual American Diabetes Association ... Test to find out if they are at risk for developing Type 2 diabetes. ... evening sky by programming the LAX pylons the color red. Downtown’s U.S. Bank Tower ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... team. Ruel Williamson brings his extensive knowledge of appraisals, property values, ad valorem ... the real estate valuation industry for more than 40 years. , “Ruel is ...
(Date:3/28/2017)... ... 2017 , ... The Thyroid Secret is a specialized 9-part ... program was recently launched on March 1, and Dr. Wentz discussed varied benefits ... Dr. Izabella Wentz is a licensed pharmacist and a foremost thyroid specialist. After ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... software and services, is proud to announce it has joined the National Association ... representing the interests of chronically ill, disabled, and dying Americans of all ages ...
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., ... (Mobile Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These iSAFE products ... first of their kind, the iSAFE and iSAFE Plus offer direct GPS Location and ...
Breaking Medicine News(10 mins):